175 related articles for article (PubMed ID: 25146864)
21. Mechanisms of cisplatin ototoxicity and progress in otoprotection.
Rybak LP
Curr Opin Otolaryngol Head Neck Surg; 2007 Oct; 15(5):364-9. PubMed ID: 17823555
[TBL] [Abstract][Full Text] [Related]
22. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
23. Audiologists' perceived value of ototoxicity management and barriers to implementation for at-risk cancer patients in VA: the OtoMIC survey.
Konrad-Martin D; Polaski R; DeBacker JR; Theodoroff SM; Garinis A; Lacey C; Johansson K; Mannino R; Milnes T; Hungerford M; Clark KD
J Cancer Surviv; 2023 Feb; 17(1):69-81. PubMed ID: 36729345
[TBL] [Abstract][Full Text] [Related]
24. An audit of UK audiological practice in specialist paediatric oncology centres regarding hearing assessment of children at risk of ototoxicity due to chemotherapy.
Brown ECM; Caimino C; Benton CL; Baguley DM
J Laryngol Otol; 2021 Jan; 135(1):14-20. PubMed ID: 33487183
[TBL] [Abstract][Full Text] [Related]
25. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin-associated ototoxicity amongst cervical cancer patients: A prospective cohort study in south Africa.
Paken J; Govender CD; Pillay M; Feyasa M; Sewram V
PLoS One; 2023; 18(4):e0283639. PubMed ID: 37014872
[TBL] [Abstract][Full Text] [Related]
27. Clinically accurate assessment and grading of ototoxicity.
Chang KW
Laryngoscope; 2011 Dec; 121(12):2649-57. PubMed ID: 22109766
[TBL] [Abstract][Full Text] [Related]
28. Genetic variation in Otos is associated with cisplatin-induced ototoxicity.
Spracklen TF; Whitehorn H; Vorster AA; Ramma L; Dalvie S; Ramesar RS
Pharmacogenomics; 2014 Sep; 15(13):1667-76. PubMed ID: 25410892
[TBL] [Abstract][Full Text] [Related]
29. [Ototoxicity of cisplatin in children with malignant diseases].
Hadjilaskari P; Fengler R; Hartmann R; Henze G
Klin Padiatr; 1989; 201(4):316-21. PubMed ID: 2779137
[TBL] [Abstract][Full Text] [Related]
30. Applying U.S. national guidelines for ototoxicity monitoring in adult patients: perspectives on patient populations, service gaps, barriers and solutions.
Konrad-Martin D; Poling GL; Garinis AC; Ortiz CE; Hopper J; O'Connell Bennett K; Dille MF
Int J Audiol; 2018 Sep; 57(sup4):S3-S18. PubMed ID: 29157038
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin-induced ototoxicity: transporters playing a role in cisplatin toxicity.
Waissbluth S; Daniel SJ
Hear Res; 2013 May; 299():37-45. PubMed ID: 23467171
[TBL] [Abstract][Full Text] [Related]
32. Challenges in ototoxicity monitoring in the pediatric oncology population.
Bass JK; Bhagat SP
J Am Acad Audiol; 2014 Sep; 25(8):760-74; quiz 782-3. PubMed ID: 25380122
[TBL] [Abstract][Full Text] [Related]
33. Ototoxicity management: An investigation into doctors' knowledge and practices, and the roles of audiologists in a tertiary hospital.
Wium A; Gerber B
S Afr J Commun Disord; 2016 Dec; 63(1):e1-e15. PubMed ID: 28155308
[TBL] [Abstract][Full Text] [Related]
34. A Randomized Controlled Trial Using Automated Technology for Improving Ototoxicity Monitoring in VA Oncology Patients.
Konrad-Martin D; O'Connell Bennett K; Garinis A; McMillan GP
Am J Audiol; 2021 Oct; 30(3S):870-886. PubMed ID: 34582263
[TBL] [Abstract][Full Text] [Related]
35. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
Knight KR; Kraemer DF; Winter C; Neuwelt EA
J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
[TBL] [Abstract][Full Text] [Related]
36. Audiological monitoring for ototoxic tuberculosis, human immunodeficiency virus and cancer therapies in a developing world setting.
Harris T; Peer S; Fagan JJ
J Laryngol Otol; 2012 Jun; 126(6):548-51. PubMed ID: 22459550
[TBL] [Abstract][Full Text] [Related]
37. Distortion product otoacoustic emissions test is useful in children undergoing cisplatin treatment.
Toral-Martiñón R; Shkurovich-Bialik P; Collado-Corona MA; Mora-Magaña I; Goldgrub-Listopad S; Shkurovich-Zaslavsky M
Arch Med Res; 2003; 34(3):205-8. PubMed ID: 14567400
[TBL] [Abstract][Full Text] [Related]
38. [Ototoxicity of cisplatin].
Ivanov SA; Zhuravskiĭ SG; Galagudza MM
Vestn Otorinolaringol; 2012; (4):82-7. PubMed ID: 23035268
[TBL] [Abstract][Full Text] [Related]
39. Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria.
Waissbluth S; Peleva E; Daniel SJ
Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1187-1196. PubMed ID: 27245751
[TBL] [Abstract][Full Text] [Related]
40. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
